UNCY UNCY
Company Profile ↓Company Overview
UNCY (UNCY) is a publicly traded company listed on with a market capitalization of $115.66M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +24.52% |
| 6 Months: | -24.42% |
| 3 Months: | -35.27% |
| 1 Month: | -3.68% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross3d ago
- RSI (14)44.96 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 38.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 951.00K | 675.00K | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.99M | 6.96M | 7.34M | 7.22M | 8.44M |
| Operating Income | -336.00K | -626.00K | -731.00K | -779.00K | -4.71M | -3.54M | -3.64M | -5.55M | -4.20M | -4.32M | -5.94M | -9.20M | -7.40M | -6.25M | - | -7.99M | -6.96M | -7.34M | -7.22M | -8.44M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 720.00K | -6.30M | -5.85M | -14.49M | -12.61M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.00K | 13.00K | 15.00K | 27.00K | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 570.00K | -6.45M | -6.01M | -14.67M | -12.82M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -338.00K | -702.00K | -964.00K | -1.10M | -5.20M | -3.54M | -3.64M | -5.56M | -14.57M | -3.84M | -4.33M | -20.96M | 9.86M | -4.10M | - | 570.00K | -6.45M | -6.01M | -14.67M | -12.82M |
| Diluted EPS | - | - | -0.11 | -0.13 | -0.37 | -0.24 | -0.24 | -0.37 | -0.97 | -0.29 | -0.13 | -0.61 | -1.50 | -0.46 | - | -0.50 | -0.52 | -0.33 | - | -0.54 |
| R&D Expense | 182.00K | 304.00K | 450.00K | 493.00K | 3.78M | 1.93M | 1.86M | 4.80M | 3.03M | 2.27M | 3.37M | 6.81M | 4.87M | 3.04M | - | 2.17M | 1.75M | 2.96M | - | 1.61M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 951.00K | 675.00K | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 19.00M | 21.45M | 32.12M | 29.52M |
| Operating Income | -2.02M | - | -18.05M | -20.77M | -32.12M | -29.52M |
| EBITDA | - | - | -17.89M | -30.18M | -36.23M | -25.91M |
| Interest Expense | - | - | 6.00K | 82.00K | 71.00K | 71.00K |
| Pretax Income | - | - | -18.06M | -30.54M | -36.73M | -26.55M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -2.26M | - | -18.06M | -30.54M | -36.73M | -26.55M |
| Diluted EPS | - | - | -12.00 | -12.80 | -5.65 | -1.67 |
| R&D Expense | 1.01M | 6.08M | 12.44M | 12.90M | 20.01M | 9.12M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 204.00K | - | 2.82M | 14.19M | 31.67M | 49.13M |
| Current Assets | - | - | - | 2.64M | 13.40M | 30.95M | 48.96M |
| Cash & Equivalents | - | - | - | 455.00K | 9.70M | 26.14M | 29.20M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 2.88M | - | 3.28M | 18.00M | 24.24M | 18.94M |
| Current Liabilities | - | 2.88M | - | 3.28M | 17.53M | 24.12M | 18.94M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 201.00K | 811.00K | 773.00K | 199.00K |
| Total Equity | -884.00K | -2.67M | - | -466.00K | -3.81M | 7.43M | 30.20M |
| Shares Outstanding | - | - | - | 1.52M | 3.48M | 11.38M | 22.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.46M | - | -15.65M | -18.28M | -28.57M | -31.32M |
| Investing Cash Flow | - | - | -2.00K | -12.00K | -72.00K | -12.10M |
| Financing Cash Flow | 1.44M | - | -471.00K | 27.54M | 45.09M | 46.47M |
| Capital Expenditure | - | - | -2.00K | -12.00K | -72.00K | -24.00K |
| Free Cash Flow | - | - | -15.65M | -18.30M | -28.65M | -31.34M |
| Net Change in Cash | - | - | -16.12M | 9.25M | 16.44M | 3.06M |
| Dividends Paid | - | - | - | 900.00K | 1.09M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | -1,898.2% | -3,077.6% | - | - |
| Net Margin % | - | - | -1,898.8% | -4,525.0% | - | - |
| ROE % | 84.8% | - | 3,875.1% | 801.9% | -494.3% | -87.9% |
| ROCE % | 75.6% | - | 3,873.8% | 621.4% | -425.5% | -97.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for UNCY
Hyperphosphatemia Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Novel Therapeutics and Rising CKD Burden | DelveInsight
Recently published Hyperphosphatemia Market Insights report includes a comprehensive understanding of current treatment practices, hyperphosphatemia emerging drugs, market share of individual therapies, and current and forecasted market siz…
Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies
In late June 2026, Unicycive Therapeutics received a Complete Response Letter from the FDA on its resubmitted oxylanthanum carbonate NDA, citing unresolved third-party manufacturing deficiencies while raising no new clinical efficacy or saf…
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval
Unicycive Therapeutics said on Tuesday that the U.S. Food and Drug Administration has again refused to approve its drug oxylanthanum carbonate.
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.9%
Top Midday Decliners
Unicycive Therapeutics (UNCY) said Tuesday it has received a Complete Response Letter from the US Fo
UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time?
Unicycive Therapeutics said it received a Complete Response Letter from the U.S. Food and Drug Administration due to previously identified deficiencies at a third-party manufacturing facility.
UNCY — Frequently Asked Questions
What is the current share price of UNCY?
As of 2026-08-05 17:25 PDT, UNCY trades at $5.23 on NASDAQ/NYSE. Its 52-week range is $3.74 to $8.56.
What is the market capitalisation of UNCY?
UNCY has a market capitalisation of $115.66M on NASDAQ/NYSE.
What is the P/E ratio of UNCY?
UNCY trades at a trailing price-to-earnings (P/E) ratio of -3.13. Its price-to-book (P/B) ratio is 3.83.
What is the return on equity (ROE) of UNCY?
UNCY has a return on equity (ROE) of -87.94%. Its return on capital employed (ROCE) is -97.75%.
Is UNCY a good stock to buy?
This page provides a data-driven analysis of UNCY, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.